Fabio Savarese

1.7k total citations
19 papers, 868 citations indexed

About

Fabio Savarese is a scholar working on Molecular Biology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Fabio Savarese has authored 19 papers receiving a total of 868 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 6 papers in Hematology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Fabio Savarese's work include Protein Degradation and Inhibitors (8 papers), Multiple Myeloma Research and Treatments (5 papers) and CRISPR and Genetic Engineering (3 papers). Fabio Savarese is often cited by papers focused on Protein Degradation and Inhibitors (8 papers), Multiple Myeloma Research and Treatments (5 papers) and CRISPR and Genetic Engineering (3 papers). Fabio Savarese collaborates with scholars based in Austria, Germany and United States. Fabio Savarese's co-authors include Anton Wutz, Thomas Jenuwein, Alexander Kohlmaier, Joost H.A. Martens, Monika Lachner, Michaela Herzig, Meinrad Busslinger, Rudolf Jaenisch, Maria Novatchkova and Gerhard Christofori and has published in prestigious journals such as Journal of Clinical Oncology, Genes & Development and Molecular and Cellular Biology.

In The Last Decade

Fabio Savarese

19 papers receiving 854 citations

Peers

Countries citing papers authored by Fabio Savarese

Since Specialization

Citations

This map shows the geographic impact of Fabio Savarese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio Savarese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio Savarese more than expected).

Fields of papers citing papers by Fabio Savarese

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio Savarese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio Savarese. The network helps show where Fabio Savarese may publish in the future.

Co-authorship network of co-authors of Fabio Savarese

This figure shows the co-authorship network connecting the top 25 collaborators of Fabio Savarese. A scholar is included among the top collaborators of Fabio Savarese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabio Savarese. Fabio Savarese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Abstract 2667: Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation 2022 ·Cancer Research ·Irene C. Waizenegger, Hengyu Lu, Claus Thamer, Fabio Savarese, Daniel Gerlach, Dorothea Rudolph, Christopher P. Vellano, Marcelo Marotti, John V. Heymach, Scott Kopetz, Timothy P. Heffernan, Joseph R. Marszalek, Mark Petronczki, Marco H. Hofmann, Norbert Kraut	12
2	Vertical pathway inhibition with a SOS1::KRAS inhibitor enhances the efficacy of KRAS G12C inhibitors, delays feedback resistance and demonstrates durable response 2020 ·European Journal of Cancer ·Fabio Savarese, Michael Gmachl, Lorenzo Federico, F. Trapani, Daniel Gerlach, Joseph R. Daniele, Ningping Feng, (unknown), (unknown), Jonathan Huang, Dorothea Rudolph, Irene C. Waizenegger, Jürgen Ramharter, Christopher P. Vellano, Mark Petronczki, Joseph R. Marszalek, Timothy P. Heffernan, Darryl B. McConnell, Norbert Kraut, Marco H. Hofmann	1
3	Abstract 5194: Epigenomic and transcriptional profiling of CRC cell lines with distinct response patterns to the BET inhibitor BI 894999 2019 ·Fabio Savarese, Daniel Gerlach, (unknown), (unknown), (unknown), Onur Kaya, Norbert Schweifer, Ulrike Tontsch-Grunt, Norbert Kraut	1
4	Abstract 5194: Epigenomic and transcriptional profiling of CRC cell lines with distinct response patterns to the BET inhibitor BI 894999 2019 ·Cancer Research ·Fabio Savarese, Daniel Gerlach, (unknown), (unknown), (unknown), Onur Kaya, Norbert Schweifer, Ulrike Tontsch-Grunt, Norbert Kraut	2
5	Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo 2018 ·Cancer Letters ·Ulrike Tontsch-Grunt, Dorothea Rudolph, Irene C. Waizenegger, Anke Baum, Daniel Gerlach, Harald Engelhardt, Melanie Wurm, Fabio Savarese, Norbert Schweifer, Norbert Kraut	34
6	The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML 2018 ·Oncogene ·Daniel Gerlach, Ulrike Tontsch-Grunt, Anke Baum, Johannes Popow, Dirk Scharn, Marco H. Hofmann, Harald Engelhardt, Onur Kaya, (unknown), Norbert Schweifer, Thomas Gerstberger, Johannes Zuber, Fabio Savarese, Norbert Kraut	66
7	Effects of the novel BET inhibitor BI 894999 on upregulation of HEXIM1 in cancer cells and on antitumor activity in xenograft tumor models. 2016 ·Journal of Clinical Oncology ·Ulrike Tontsch-Grunt, Fabio Savarese, Anke Baum, Dirk Scharn, Daniel Gerlach, Marco H. Hofmann, Onur Kaya, Norbert Schweifer, Harald Engelhardt, Hanny Musa, (unknown), Gerd Munzert, (unknown)	1
8	Combination of the novel BET inhibitor BI 894999 with CDK9 inhibition suggests a promising regimen for the treatment of AML 2016 ·European Journal of Cancer ·Ulrike Tontsch-Grunt, Fabio Savarese, Anke Baum, D.M. Scharn, Daniel Gerlach, Marco H. Hofmann, (unknown), Norbert Schweifer, (unknown), (unknown), (unknown), Gerd Munzert, Norbert Kraut	4
9	Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia 2015 ·Journal of Pharmacology and Experimental Therapeutics ·Dorothea Rudolph, (unknown), Claudia Blaukopf, Christoph Sommer, Daniel W. Gerlich, Mareike Roth, Ulrike Tontsch-Grunt, Andreas Wernitznig, Fabio Savarese, Marco H. Hofmann, (unknown), (unknown), Markus Reschke, Pilar Garin‐Chesa, Johannes Zuber, Jürgen Moll, Günther R. Adolf, Norbert Kraut	50
10	Abstract B79: BI 894999, a novel BET inhibitor: Treatment of hematological malignancies by repression of super-enhancer driven oncogenes 2015 ·Molecular Cancer Therapeutics ·Ulrike Tontsch-Grunt, Fabio Savarese, Daniel Gerlach, Davide Gianni, Anke Baum, Dirk Scharn, Harald Engelhardt, Onur Kaya, Norbert Schweifer, Thomas Gerstberger, Norbert Kraut	4
11	Satb1 and Satb2 Are Dispensable for X Chromosome Inactivation in Mice 2012 ·Developmental Cell ·Robert Nechanitzky, (unknown), Fabio Savarese, (unknown), Rudolf Grosschedl	22
12	Satb1 and Satb2 regulate embryonic stem cell differentiation and Nanog expression 2009 ·Genes & Development ·Fabio Savarese, (unknown), Robert Nechanitzky, (unknown), Carlos‐Filipe Pereira, Rudolf Engelke, Keiko Takahashi, Thomas Jenuwein, Terumi Kohwi-shigematsu, Amanda G. Fisher, Rudolf Grosschedl	111
13	‘Extremely diluted solutions’ as multi-variable systems 2006 ·Journal of Thermal Analysis and Calorimetry ·Vittorio Elia, (unknown), (unknown), E. Napoli, Marcella Niccoli, Fabio Savarese	37
14	Tumor progression induced by the loss of E-cadherin independent of β-catenin/Tcf-mediated Wnt signaling 2006 ·Oncogene ·Michaela Herzig, Fabio Savarese, Maria Novatchkova, Henrik Semb, Gerhard Christofori	101
15	Hematopoietic Precursor Cells Transiently Reestablish Permissiveness for X Inactivation 2006 ·Molecular and Cellular Biology ·Fabio Savarese, (unknown), Rudolf Jaenisch, Meinrad Busslinger, Anton Wutz	98
16	Interaction of “extremely diluted solutions” with aqueous solutions of hydrochloric acid and sodium hydroxide 2006 ·Journal of Molecular Liquids ·Vittorio Elia, (unknown), (unknown), Maria Montanino, E. Napoli, Marcella Niccoli, (unknown), Fabio Savarese	16
17	A Chromosomal Memory Triggered by Xist Regulates Histone Methylation in X Inactivation 2004 ·PLoS Biology ·Alexander Kohlmaier, Fabio Savarese, Monika Lachner, Joost H.A. Martens, Thomas Jenuwein, Anton Wutz	300
18	Initial evaluation of a new optic laryngoscope blade 2002 ·Journal of Clinical Anesthesia ·Scott D. Markowitz, Paul F. White, Tijani Issioui, Stephanie B. Jones, Kevin W. Klein, (unknown), (unknown), Giovanni Pittoni, Fabio Savarese	5
19	Neurological deficit following spinal anaesthesia: MRI and CT evidence of spinal cord gas embolism 1999 ·Neuroradiology ·Enrico Tedeschi, (unknown), Fabio Savarese, (unknown), Enrico Di Salvo, Arturo Brunetti, A Sodano	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact